Isis Pharmaceuticals Inc (ISIS.OQ)
29.32USD
10:57am EDT
$0.47 (+1.63%)
$28.85
$29.13
$30.00
$28.90
105,693
508,220
$34.30
$7.55
About
Overall
| Beta: | 1.11 |
| Market Cap (Mil.): | $3,222.41 |
| Shares Outstanding (Mil.): | 111.70 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ISIS.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 47.13 | 37.76 |
| EPS (TTM): | -0.43 | -- | -- |
| ROI: | -9.68 | -2.58 | 18.76 |
| ROE: | -24.52 | -2.66 | 19.59 |
Isis eyes nationwide mobile payments launch this year
NEW YORK - Isis, a venture of three of the top U.S. mobile providers, said on Tuesday it would expand its much-delayed mobile payments service nationwide later in 2013 after it tested the concept with consumers in two markets.
Isis Pharma drug reduces blood fat by 64 pct in mid-stage study
- Isis Pharmaceuticals Inc said its experimental drug reduced the level of triglycerides, a type of fat in the blood that increases the risk of heart diseases, by up to 64 percent in a mid-stage trial.
Isis Pharma drug reduces blood fat by 64 pct in mid-stage study
July 22 - Isis Pharmaceuticals Inc said its experimental drug reduced the level of triglycerides, a type of fat in the blood that increases the risk of heart diseases, by up to 64 percent in a mid-stage trial.
Isis shares jump after experimental drug cuts blood fat
- Shares of Isis Pharmaceuticals Inc rose as much as 24 percent after the drugmaker said its experimental drug reduced triglycerides, a type of fat, in blood and increased the level of "good" cholesterol.
Roche to use Isis's technology to develop brain disorder drug
- Isis Pharmaceuticals Inc said it will form an alliance with Swiss drugmaker Roche Holding AG to develop treatments for Huntington's disease, a genetic brain disorder, based on the U.S. company's technology.
Roche to use Isis's technology to develop brain disorder drug
April 8 - Isis Pharmaceuticals Inc said it will form an alliance with Swiss drugmaker Roche Holding AG to develop treatments for Huntington's disease, a genetic brain disorder, based on the U.S. company's technology.
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $29.19 | -0.04 |
| Novartis AG (NOVN.VX) | CHF66.60 | +0.35 |
| Merck & Co., Inc. (MRK.N) | $48.10 | -0.07 |
| Roche Holding Ltd. (ROG.VX) | CHF228.00 | -3.50 |
| GlaxoSmithKline plc (GSK.L) | 1,706.50p | +22.50 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

